2seventy Bio, INC

Bristol-Myers Squibb finalizes its acquisition of 2seventy bio for $5.00 per share, totaling approximately $264.6 million, leading to delisting from NASDAQ and significant management changes.

2seventy bio announced its first quarter 2025 financial results, highlighting Abecma's U.S. commercial performance and progress toward acquisition by Bristol Myers Squibb (BMS), expected to close in the second quarter of 2025.

2seventy bio announces a definitive merger agreement to be acquired by Bristol Myers Squibb (BMS) for $5.00 per share in cash, alongside reporting its Q4 and full year 2024 financial results, highlighting a focus on Abecma commercialization and cost structure streamlining.

Bristol Myers Squibb will acquire 2seventy bio in an all-cash transaction for $5.00 per share, valuing the company at approximately $286 million.

2seventy bio announces preliminary U.S. Abecma sales of $242 million for 2024 and targets quarterly breakeven by the end of 2025.

2seventy bio, Inc. announced the appointment of Jessica Snow as its new Chief Operating Officer, effective January 6, 2025.

2seventy bio announced its Q1 2025 results, highlighting a net income of $0.5 million and progress on its merger agreement with Bristol-Myers Squibb.

2seventy bio's Q3 2024 results reflect a strategic shift towards Abecma commercialization, following the sale of its oncology and autoimmune programs to Regeneron and its megaTAL program to Novo Nordisk.

2seventy bio reports a net income of $24.9 million for Q2 2024, driven by strategic asset sales and a focus on Abecma commercialization.

2seventy bio reports a net loss of $52.7 million for Q1 2024 and completes a strategic realignment focusing on Abecma commercialization.

2seventy bio files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

2seventy bio, Inc. reports its 2024 financial results, highlighting Abecma's commercial performance and strategic realignment, while awaiting a proposed acquisition by Bristol-Myers Squibb (BMS).

2seventy bio modifies its royalty payment terms with the National Institutes of Health and strategically realigns to concentrate on the commercialization of Abecma.

Director Sarah JS Glickman reports the disposal of shares and stock options in 2seventy bio, Inc. following the completion of a merger with Bristol-Myers Squibb Company.

Casdin Capital, LLC reports the tendering of shares and conversion of stock options and restricted stock units following the merger of 2seventy bio, Inc. with a subsidiary of Bristol-Myers Squibb Company.

Director Nick Leschly reports disposition of shares and derivative securities of 2seventy bio, Inc. following the merger with Bristol-Myers Squibb.

Victoria Eatwell, CFO of 2seventy bio, reports the disposal of shares and options following the merger with Bristol-Myers Squibb, where 2seventy bio became a wholly-owned subsidiary.

Jessica Snow, Chief Operating Officer of 2seventy bio, Inc., reports the disposition of common stock and stock options due to the merger with Bristol-Myers Squibb Company.

Director Wei Lin reports the disposal of common stock and stock options in 2seventy bio following the completion of a merger with Bristol-Myers Squibb, where shares were converted to cash at $5.00 per share.

Seventy Bio, Inc. has filed a definitive proxy statement with the SEC.

2seventy bio, Inc. has filed its definitive proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for June 10, 2024, covering the election of directors and ratification of the independent accounting firm.

2seventy bio appoints Eli Casdin and Charles Newton to its Board of Directors and acknowledges Engine Capital's nomination of two candidates for election at the upcoming annual meeting.

Glazer Capital, LLC and Paul J. Glazer have reported a complete divestment of their beneficial ownership in 2seventy bio, Inc., holding 0% of common stock.

Beryl Capital Management and its affiliates have reported a complete divestiture of their beneficial ownership in 2seventy bio, Inc., holding 0% of common stock.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a negligible 0.0% beneficial ownership in 2SEVENTY BIO, INC. common stock.